Sodium bicarbonate

Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcased in Podium Presentation at 2022 EULAR Congress

Retrieved on: 
Wednesday, June 1, 2022
European Alliance, Pain, Congress, EULAR, Steroid, Gout, Toxicity, Sodium bicarbonate, PROMIS, University, MI, Nonsteroidal anti-inflammatory drug, GLOBE, Patient, Population, Hospital, MPH, Colchicine, Swelling, Pharmaceutical industry, Medical imaging, Rheumatology

Dr. Khanna commented, There remains a dearth of effective, approved treatments to relieve the intense debilitating pain that accompanies acute gout flares.

Key Points: 
  • Dr. Khanna commented, There remains a dearth of effective, approved treatments to relieve the intense debilitating pain that accompanies acute gout flares.
  • Hospital admissions for acute gout flares have doubled in the U.S. over the past two decades.
  • Current options like steroids, colchicine, NSAIDs and IL-1 inhibitors are antiquated and non-selective, which results in significant toxicity and frequent drug-drug interactions.
  • DYV702 showed significant improvement in PROMIS PF-20 scores at 24 hours, with 16.7 for DYV702 vs. 9.4 for control (p

Church & Dwight Webcasts Fireside Chat at the dbAccess Global Consumer Conference

Retrieved on: 
Thursday, June 2, 2022
Manufacturing, Home Goods, Retail, Specialty, Chemicals, Plastics, ARM, EDT, Company, Conference, CEST, Sodium bicarbonate, Investor, FIRST, NYSE, HAMMER, CHD

Church & Dwight Co., Inc. (NYSE: CHD) will participate in a fireside chat at the dbAccess Global Consumer Conference on Thursday, June 16 at 9:15 a.m. CEST (3:15 a.m. EDT).

Key Points: 
  • Church & Dwight Co., Inc. (NYSE: CHD) will participate in a fireside chat at the dbAccess Global Consumer Conference on Thursday, June 16 at 9:15 a.m. CEST (3:15 a.m. EDT).
  • A link to the broadcast will be provided through the Investors section of Church & Dwights website at http://investor.churchdwight.com/investors/news-events .
  • Church & Dwight Co., Inc. manufactures and markets a wide range of personal care, household and specialty products under the ARM & HAMMER brand name and other well-known trademarks.
  • Church & Dwight Co., Inc. founded in 1846, is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda.

Rayonier Advanced Materials Appoints De Lyle W. Bloomquist as President and Chief Executive Officer

Retrieved on: 
Tuesday, May 31, 2022
Natural Resources, Manufacturing, Packaging, Forest Products, Chemicals, Plastics, Senior, MBA, Assistant, Board of directors, Company, Tata Chemicals, EBITDA, Private Securities Litigation Reform Act, Rutgers University, U.S. Securities and Exchange Commission, Sodium bicarbonate, Â, LaPorte CPAs and Business Advisors, EDO Corporation, Food, Tepper School of Business, Language, Assistant General Counsel of the Navy (Research, Development and Acquisitions), Solution, Avnet, Annual report, Industry, Retirement, Triple accreditation, Board, Program, Paper, GCM, General counsel, Brigham Young University, Mineral, Mining, Business, NYSE, Carnegie Mellon University, CEO, Rayonier Advanced Materials, Management

Rayonier Advanced Materials Inc. (NYSE:RYAM) (the Company) today announced that De Lyle W. Bloomquist has been appointed President and Chief Executive Officer of the Company, effective immediately.

Key Points: 
  • Rayonier Advanced Materials Inc. (NYSE:RYAM) (the Company) today announced that De Lyle W. Bloomquist has been appointed President and Chief Executive Officer of the Company, effective immediately.
  • Mr. Bloomquist succeeds Vito J. Consiglio, who has stepped down as President and Chief Executive Officer of the Company, and as a member of the Companys Board of Directors (the Board), with the mutual agreement of the Board.
  • I also want to thank Vito for his contributions and service to Rayonier Advanced Materials and wish him the best in his future endeavors.
  • Rayonier Advanced Materials assumes no obligation to update these statements except as is required by law.

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

Retrieved on: 
Wednesday, May 18, 2022
Medical Devices, Health, General Health, Research, Cardiology, Science, Risk, Cardiomyopathy, International Journal of Cardiology, Sodium bicarbonate, Survival, US Foods, U.S. Securities and Exchange Commission, EDT, Heparin-induced thrombocytopenia, PCI, US FDA, Patient, Multimedia, ABMD, NASDAQ, Decompensation, US, Meta-analysis, Myocardial infarction, Canadian International Council, ASL, Mortality, Heart, Kidney, FDA, U.S. FDA, SCAI, Cardiogenic shock, Bleeding, Heparin, Pulmonary artery, SHOCK, Heart failure, Inferior vena cava, Registry, Lung, Society, Security (finance), PubMed, Cochrane, MD, Pharmaceutical industry, Medical device, Cardiology, Impella, Abiomed

The patients were divided into two groups those who received Impella support pre-PCI (n=2,970) and those who received Impella support during or post-PCI (n=3,840).

Key Points: 
  • The patients were divided into two groups those who received Impella support pre-PCI (n=2,970) and those who received Impella support during or post-PCI (n=3,840).
  • The data showed significantly reduced short-term mortality rates in AMICS patients who received Impella support pre-PCI, compared to those who received Impella support during or post-PCI (37.2% vs 53.6%, p=0.002).
  • Details of the presentation and the study abstract are available on the SCAI 2022 Scientific Sessions website .
  • SCAI also provides Abiomed an opportunity to highlight its latest FDA approval, which simplifies Impella management with the goal of improving patient outcomes.

UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting

Retrieved on: 
Friday, May 13, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Urination, Clothing, Fever, Pain, Nausea, Blood, LG, Swelling, Medicine, Neoplasm, Regulation of tobacco by the U.S. Food and Drug Administration, Urine, Food, Sodium bicarbonate, UNC, Thermoregulation, Time-invariant system, Breast milk, Patient, Bone marrow, Patient Information Advisory Group, Associate, Stomach, Ernest, University of North Carolina at Charlotte, Abdomen, Kidney, Birth, UTUC, Female, AUA, University, Technology, Vomiting, Skin, H. Lee Moffitt Cancer Center & Research Institute, Urinary tract infection, Fatigue, Twitter, Water, Perforation, Medical imaging, Health insurance, Birth control, Tanning (leather), Pharmaceutical industry, Phosphorus, Urology, Mitomycins

It is approved for administration in a retrograde manner via ureteral catheter or antegrade through nephrostomy tube.

Key Points: 
  • It is approved for administration in a retrograde manner via ureteral catheter or antegrade through nephrostomy tube.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Before receiving JELMYTO, tell your healthcare provider about all your medical conditions, including if you:
    are pregnant or plan to become pregnant.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.

UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Tuesday, May 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ureter, Birth, Swelling, Kidney, Safety, Urination, Patient Information Advisory Group, Risk, Skin, Female, NMIBC, View, SEC, Trial of the century, Technology, Nausea, Stomach, Pain, Twitter, Water, Perforation, Company, Probability, Patient, Urine, Clinical trial, FDA, Nephrectomy, Sodium bicarbonate, Vomiting, Private Securities Litigation Reform Act, Bone marrow, Medicine, Neoplasm, NDA, Time, Fatigue, UTUC, Clothing, Growth, Man, COVID-19, Transitional cell carcinoma, Abdomen, Fever, Cancer, Blood, Orphan drug, Urinary bladder, Urinary tract infection, Adult, Breast milk, Transitional epithelium, Recurrence, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Mitomycins, Mitomycin C, Pharmakon—Danish College of Pharmacy Practice

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005510/en/

Church & Dwight to Present at the 2022 Goldman Staples Forum

Retrieved on: 
Friday, May 6, 2022
Other Manufacturing, Supermarket, Chemicals, Plastics, Food, Beverage, Cosmetics, Manufacturing, Retail, Department Stores, FIRST, Company, NYSE, HAMMER, ARM, CHD, Sodium bicarbonate, Investor

Church & Dwight Co., Inc. (NYSE: CHD) will participate in a fireside chat at the Goldman Sachs Global Staples Forum on Tuesday, May 17 at 8:15 a.m.

Key Points: 
  • Church & Dwight Co., Inc. (NYSE: CHD) will participate in a fireside chat at the Goldman Sachs Global Staples Forum on Tuesday, May 17 at 8:15 a.m.
  • A link to the broadcast will be provided through the Investors section of Church & Dwights website at http://investor.churchdwight.com/investors/news-events .
  • Church & Dwight Co., Inc. manufactures and markets a wide range of personal care, household and specialty products under the ARM & HAMMER brand name and other well-known trademarks.
  • Church & Dwight Co., Inc. founded in 1846, is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda.

Church & Dwight to Report First Quarter 2022 Results

Retrieved on: 
Monday, April 4, 2022
Retail, Chemicals, Plastics, Convenience Store, Home Goods, Manufacturing, Supermarket, CHD, Company, NYSE, Investor relations, Sodium bicarbonate, FIRST, ARM

Church & Dwight Co., Inc. (NYSE:CHD) will host a conference call to discuss first quarter 2022 earnings results on April 28, 2022 at 10:00 a.m. Eastern time.

Key Points: 
  • Church & Dwight Co., Inc. (NYSE:CHD) will host a conference call to discuss first quarter 2022 earnings results on April 28, 2022 at 10:00 a.m. Eastern time.
  • To participate, dial 877-322-9846 within the U.S. and Canada, or 631-291-4539 internationally, using access code 7619748.
  • A replay will be available two hours after the call at 855-859-2056 using the same access code.
  • Church & Dwight Co., Inc. (NYSE: CHD) founded in 1846, is the leading U.S. producer of sodium bicarbonate, popularly known as baking soda.

UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, March 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Private Securities Litigation Reform Act, Risk, Adult, Fatigue, SEC, Urination, Cancer, Medicine, Neoplasm, Breast milk, Sodium bicarbonate, Technology, Twitter, UTUC, Patient Information Advisory Group, Trial of the century, Time, NDA, Ureter, Urine, Recurrence, Transitional cell carcinoma, Kidney, Nausea, Pain, View, Clothing, Perforation, Swelling, Female, Nephrectomy, Vomiting, NMIBC, Clinical trial, Growth, Urinary tract infection, Man, Urinary bladder, FDA, Patient, Birth, Abdomen, Company, Stomach, ATLAS, Skin, Bone marrow, Fever, Safety, Orphan drug, COVID-19, Arm, Transitional epithelium, Blood, TURBT, Water, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Mitomycin C, Mitomycins, JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ENVISION TRIAL, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ENVISION TRIAL, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220321005260/en/

Inworld AI Raises Investment from BITKRAFT Ventures, to Bring AI-Powered Virtual Characters to Metaverse and Games

Retrieved on: 
Friday, March 4, 2022
Riot Games, Kleiner Perkins, Unity, Activision Blizzard, Life, Research, Industry, Sandbox, Apple, Meta, Matrix, DeepMind, CRV, Sodium bicarbonate, Acquisition, CEO, NASA RealWorld-InWorld Engineering Design Challenge, Epic Games, API.AI, AI, Computer vision, VR, Human, GLOBE, Academy Awards, Cryptocurrency, Video game, Copper, Google

The investment will be used to scale the team as the company strategically expands into metaverse applications and gaming.

Key Points: 
  • The investment will be used to scale the team as the company strategically expands into metaverse applications and gaming.
  • The company is on a mission to enable developers and creators to build virtual characters that support natural multimodal interactions with users.
  • Virtual characters created using Inworld AIs platform mimic the cognitive abilities of humans by leveraging a combination of AI technologies including natural language understanding and generation, computer vision, and reinforcement learning.
  • For more information about Inworld AI, please visit https://www.inworld.ai/
    Inworld AI provides a developer platform for creating AI-powered virtual human agents to populate immersive realities including the metaverse, VR/AR, games, and virtual worlds.